| Targeting mutations in cancer MR Waarts, AJ Stonestrom, YC Park, RL Levine The Journal of clinical investigation 132 (8), 2022 | 159 | 2022 |
| Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors A Dunbar, KL Bolton, SM Devlin, F Sanchez-Vega, J Gao, JV Mones, ... Blood, The Journal of the American Society of Hematology 137 (15), 2103-2113, 2021 | 86 | 2021 |
| PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN F Pastore, N Bhagwat, A Pastore, A Radzisheuskaya, A Karzai, ... Cancer discovery 10 (11), 1742-1757, 2020 | 65 | 2020 |
| CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis AJ Dunbar, D Kim, M Lu, M Farina, RL Bowman, JL Yang, Y Park, ... Blood, The Journal of the American Society of Hematology 141 (20), 2508-2519, 2023 | 32 | 2023 |
| Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms AJ Dunbar, RL Bowman, YC Park, K O'Connor, F Izzo, RM Myers, ... Cancer discovery 14 (5), 737-751, 2024 | 15 | 2024 |
| The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I … S Rai, J Stetka, M Usart, H Hao-Shen, Y Park, R Houston, ... Blood 140 (Supplement 1), 6722-6723, 2022 | 13 | 2022 |
| Detection of marker-free precision genome editing and genetic variation through the capture of genomic signatures P Billon, TS Nambiar, SB Hayward, MP Zafra, EM Schatoff, K Oshima, ... Cell reports 30 (10), 3280-3295. e6, 2020 | 11 | 2020 |
| Jak2V617F reversible activation shows an essential requirement for Jak2V617F in myeloproliferative neoplasms (MPNs) A Dunbar, RL Bowman, Y Park, F Izzo, RM Myers, A Karzai, W Jun Kim, ... Blood 140 (Supplement 1), 803-804, 2022 | 8 | 2022 |
| Epigenetic dysregulation of myeloproliferative neoplasms A Dunbar, Y Park, R Levine Hematology/oncology clinics of North America 35 (2), 237, 2021 | 7 | 2021 |
| Developing a membrane-proximal CD33-targeting CAR T cell R Freeman, S Shahid, AG Khan, SC Mathew, S Souness, ER Burns, ... Journal for immunotherapy of cancer 12 (5), e009013, 2024 | 3 | 2024 |
| Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms A Dunbar, M Lu, M Farina, Y Park, J Yang, D Kim, A Karzai, ME Salama, ... Blood 136, 6-7, 2020 | 3 | 2020 |
| Aberrant responsiveness of erythropoiesis to iron deficiency in polycythemia vera M Feola, D Moskop, N Terra, YC Park, A Dunbar, RL Levine, R Hoffman, ... Blood 134, 429, 2019 | 3 | 2019 |
| CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells MR Waarts, S Mowla, M Boileau, AR Martinez Benitez, J Sango, M Bagish, ... Cancer Discovery 14 (10), 1860-1878, 2024 | 2 | 2024 |
| Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation RL Bowman, A Dunbar, T Mishra, W Xiao, MR Waarts, IF Maestre, ... Biorxiv, 2022.05. 18.492524, 2022 | 2 | 2022 |
| CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis A Dunbar, D Kim, M Lu, M Farina, JL Yang, Y Park, F Gobbo, P Verachi, ... bioRxiv, 2021.12. 08.471791, 2021 | 2 | 2021 |
| In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy RL Bowman, AJ Dunbar, T Mishra, W Xiao, MR Waarts, IF Maestre, ... Cancer cell 42 (11), 1955-1969. e7, 2024 | | 2024 |
| TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2V617F Mutant Mice M Levy, H Li, A Dunbar, Z Huang, Y Park, M Lu, PN Phattalung, ... Blood 144, 8, 2024 | | 2024 |
| Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials A Dunbar, HE Kosiorek, A Krishnan, E McGovern, Y Park, MA Patel, ... Blood 134, 1661, 2019 | | 2019 |